Research Article

Development of Quantitative Structure-Property Relationship Models for Self-Emulsifying Drug Delivery System of 2-Aryl Propionic Acid NSAIDs

Chen-Wen Li,¹ Sheng-Yong Yang,² Rui He,¹ Wan-Jun Tao,³ and Zong-Ning Yin¹

¹ Department of Pharmaceutics, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China

² State Key Laboratory of Biotherapy and Cancer Center, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, China

³ Department of Pharmacy, Chengdu Family Planning Guidance Institute, Chengdu, Sichuan 610041, China

Correspondence should be addressed to Zong-Ning Yin, yzn@scu.edu.cn

Received 19 May 2011; Revised 22 July 2011; Accepted 22 July 2011

Academic Editor: Xing J. Liang

Copyright © 2011 Chen-Wen Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We developed the quantitative structure-property relationships (QSPRs) models to correlate the molecular structures of surfactant, cosurfactant, oil, and drug with the solubility of poorly water-soluble 2-aryl propionic acid nonsteroidal anti-inflammatory drugs (2-APA-NSAIDs) in self-emulsifying drug delivery systems (SED DSs). The compositions were encoded with electronic, geometrical, topological, and quantum chemical descriptors. To obtain reliable predictions, we used multiple linear regression (MLR) and artificial neural network (ANN) methods for model development. The obtained equations were validated using a test set of 42 formulations and showed a great predictive power, and linear models were found to be better than nonlinear ones. The obtained QSPR models would greatly facilitate fast screening for the optimal formulations of SED DSs at the early stage of drug development and minimize experimental effort.

1. Introduction

Low water solubility of many drug candidates has been a big challenge to pharmaceutical industry since the oral delivery of these drugs may lead to low bioavailability high intra- and intersubject variability [1]. Several formulation approaches to improve solubility of these drugs have been investigated including cyclodextrins [2], micelles [3], nanoparticles [4], solid dispersions [5], and self-emulsifying drug delivery systems (SED DSs). SED DSs are isotropic mixtures of an oil, surfactant, co-surfactant and drug that form O/W emulsion or microemulsion when introduced into aqueous phases under gentle agitation [6–8]. They can enhance the oral bioavailability of hydrophobic drugs, which are attractive carriers for poorly water-soluble drugs [8–11]. Dissolution in SED DSs and no precipitation in the gastrointestinal tract are some of the prerequisites for the efficient intestinal absorption of drugs [12]. The drug solubility in SED DSs is a key parameter to select optimal formulations [13].

Pharmaceutical preparation is a complicated procedure including preformulation studies, formulation screening, technology optimization, and stability studies. Among them, screening for the optimum formulation is a crucial step. Usually, the first stage is to select suitable excipients and preparation technology through preliminary experiments, and then to screen for the optimized formulation using single-factor design, orthogonal design, or uniform design. These experimental processes are expensive and time consuming. Therefore, estimating properties using theoretical modeling is an efficient way for formulation screening. Quantitative structure-property relationships (QSPRs) are the process by which chemical structure is quantitatively correlated with its physical, chemical, or biological property. It has been widely used in pharmaceutical research [14–16] including predicting the biological activity [17], absorption [18, 19], distribution [20, 21], metabolism, excretion [22], and chemical reactivity-related toxicity [23] (ADMET) properties of drugs. However, QSPR is rarely applied in the pharmaceuticals

FIGURE 1: Molecular structures of model drugs.

TABLE 1: The selected SEDDS.

Formulation	Oil	Surfactant	Cosurfactant
1	Oleic acid	Tween20	Ethanol
2	IPM	Tween40	Ethylene glycol monoethyl ether
3	Ethyl oleate	Tween80	1, 2-propanol
4	Methyl laurate	Tween20	<i>n</i> -Butanol
5	Butyl oleate	Tween40	Isopropyl alcohol
6	Methyl oleate	Tween80	Diethylene glycol monoethyl ether
7	Butyl oleate	Tween20	Isopropyl alcohol
8	Ethyl oleate	Tween40	Ethanol

[24–26] since numerous factors might affect the preparation process. Therefore, it is a good attempt to introduce QSPR into pharmaceuticals, establishing the relationship between the property of formulation and the chemical structure of compositions by mathematical methods, which will decrease the experimental time.

The aim of this study was to develop available QSPR models for predicting the drug solubility in SEDDS. We investigated a set of poorly water-soluble 2-aryl propionic acid nonsteroidal anti-inflammatory drugs (2-APAs-NSAIDs). We then applied the model such obtained to understand the solubility mechanism of drug in SEDDS as well as to fast screen for the optimized formulations.

2. Materials and Methods

2.1. Materials. Ketoprofen was provided by Southwest Pharmaceuticals Co., Ltd. (Chongqing, China). Flurbiprofen and loxoprofen were purchased from Wuhan Yuancheng Technology Development Co., Ltd. (Wuhan, China). Ibuprofen was a gift from Hubei Biocause Pharmaceutical Co., Ltd. (Hubei, China). Naproxen was obtained from Chengdu Jinhua Pharmaceutical Co., Ltd. (Chengdu, China). Carprofen was purchased from Shandong Fangxing Technology Development Co., Ltd. (Shandong, China). All other agents were of analytical grade.

2.2. Data Collection

2.2.1. Preparation Self-Emulsifying Mixtures. SEDDSs consisted of surfactant, cosurfactant oil, and drug. Surfactants employed were Tween20, Tween40, and Tween80. Oil and cosurfactant selected in the present study had definite, simple structures and commonly used in pharmaceuticals. Table 1 shows the composition of the formulations. The weight ratio of surfactant to cosurfactant (Km) varied as 1:2, 1:1, 2:1, 3:1, and 4:1. The self-emulsifying mixtures containing oil, surfactant and cosurfactant, were prepared at a specific ratio of oil to surfactant/cosurfactant mixture (Smix), 5:95, 10:90, and 15:85 (w/w). Each component was accurately weighed in the same screw-cap tubes and mixed by gentle stirring and vortex-mixing. Model drugs were hydrophobic 2-aryl propionic acid NSAIDs including ketoprofen, ibuprofen, flurbiprofen, naproxen, loxoprofen, and carprofen. The structures of these drugs are shown in Figure 1.

2.2.2. Solubility Studies. In the study, 0.1 g self-emulsifying mixture was diluted with distilled water to 5 ml in a sealed tube and gently mixed by a Vortex mixture (Ika, Germany). An excess amount of drugs was added to the formed microemulsions or emulsions. The blend was mixed and left to equilibrate at 37°C for 48 h in a water bath and then centrifuged at 6,000 rpm for 10 min. The supernatant was

TABLE 2: Values of important descriptors.

Component	Dipole	MaxQ ⁻	MaxQ ⁺	ABSQ	E _{LUMO}	E _{HOMO}	LogD	Volume	Wiener index
Ketoprofen	4.6178	-0.1264	0.7765	9.4418	0.07479	-0.33786	1.906	167.38	724
Ibuprofen	1.9316	-0.0067	0.7825	8.4045	0.13177	-0.32242	2.150	152.63	404
Flurbiprofen	3.2118	-0.0234	0.7838	8.3569	0.09569	-0.28772	1.394	155.37	530
Naproxen	0.3521	-0.7313	0.7820	8.2233	0.09868	-0.31306	3.748	155.72	626
Loxoprofen	1.7058	-0.3306	0.3272	3.6074	0.27676	-0.27805	3.003	168.75	672
Carprofen	4.7591	-1.0815	0.7836	9.0201	0.08655	-0.29753	2.233	178.7	689
Tween HS	7.0424	-0.5202	0.6213	38.9571	0.17706	-0.40723	-4.492	749.79	44308
Tween20Ls	0.0547	-0.2885	0.1508	7.0901	0.22476	-0.41273	5.389	137.54	220
Tween40Ls	0.0546	-0.2885	0.1507	9.4410	0.22384	-0.40605	7.214	183.5	560
Tween80Ls	0.2610	-0.1646	0.1666	10.3074	0.18531	-0.33536	7.682	209.91	816
Oleic acid	2.0597	-0.1638	0.7540	12.8007	0.16604	-0.33764	5.412	231.18	1313
Ethyl oleate	2.2099	-0.1640	0.7924	13.7649	0.17516	-0.33703	7.435	257.24	1720
IPM	2.2730	-0.2715	0.8086	12.7784	0.17604	-0.40761	6.432	227.4	1072
Methyl laurate	2.3148	-0.1217	0.7871	9.8417	0.17346	-0.4139	4.793	173.9	538
Methyl oleate	2.0349	-0.1218	0.7872	13.0583	0.17314	-0.33705	7.086	243.18	1506
Butyl oleate	2.2902	-0.1522	0.7658	14.935	0.17492	-0.33731	8.415	279.88	2215
Ethanol	2.1046	-0.4459	0.4001	2.4001	0.22361	-0.43772	-0.010	38.75	4
1, 2-propanol	3.1810	-0.4491	0.4246	3.9863	0.2109	-0.42825	-0.520	54.87	18
Ethylene glycol monoethyl ether	0.4875	-0.4526	0.4074	3.9245	0.21824	-0.4152	-0.141	67.91	35
n-Butanol	2.0417	-0.2890	0.3996	3.6342	0.22567	-0.43685	0.970	60.36	20
Isopropyl alcohol	2.0903	-0.4291	0.3965	3.2827	0.21465	-0.43207	0.368	49.39	9
Diethylene glycol monoethyl ether	2.0613	-0.4526	0.4079	5.4420	0.21531	-0.41581	-0.272	98.09	120

filtered through a filter membrane (0.22 μ m), diluted with methanol to a suitable concentration range, and quantified by HPLC (see Section 2.2.3).

2.2.3. HPLC Analysis of the Model Drugs. The HPLC analysis was performed with a Waters pump 515 and a UV-VIS detector 2487. The column was a Diamasil C18 100 mm $\times$ 4.6 mm column (Dikama, China). The mobile phase consisted of a mixture of methanol, water, and phosphoric acid (20:80:0.1, v/v/v). The UV detector wavelengths were set at 254 nm (ketoprofen), 222 nm (ibuprofen), 247 nm (flurbiprofen), 273 nm (naproxen), 222 nm (loxoprofen), 300 nm (carprofen), respectively. The elution was carried out at a flow rate of 1.0 mL/min, and the temperature of column oven (PH-730A, Phenomen, China) was set to 30°C. Each measurement was repeated for three times.

2.3. Descriptor Generation and Variable Selection. Molecular descriptors are commonly used to represent the structural and physicochemical features of compositions, so that they can be used in a QSPR model. Thus, to establish a QSPR model, *Ab initio* quantum mechanical calculations were first performed for relevant molecular descriptors using Gaussian 03 software package (Gaussian 03, Gaussian, Inc., Pittsburgh, 2003.). Geometric optimization and quantum chemical, electrostatic parameters were calculated at RHF/6-31G* level. Quantum chemical parameters including the dipole moment (Dipole), the energy of the highest occupied molecular orbital (E_{HOMO}), and the lowest unoccupied molecular

orbital (E_{LUMO}) as well as electrostatic parameters including MaxQ⁻, MaxQ⁺, ABSQ, and ABSQon were obtained. In addition, Discovery Studio 1.7 package (Accelrys Inc., USA) was used to calculate parameters such as molecular volume, polar surface area, wiener index, logD, and logP. Constitutional parameters including surfactant ratio (SR), cosurfactant ratio (CoSR), and oil ratio (OR) were also calculated. Table 2 shows the values of important descriptors.

Nonionic surfactants, Tween20, Tween40, and Tween80 belong to the polyoxyethylene sorbitan family. They have similar head structures, and the difference observed in behavior is mainly due to different hydrophobic portions [27]. So each surfactant structure was cleaved into two parts: the same hydrophilic segment (HS) and a different lipophilic segment (LS); and their descriptors were calculated separately. The cleavage method was performed as in Taha et al. [26].

The role of cosurfactant in the formation of SEDDS is to increase the interfacial flexibility by extending into the surfactant interfacial monolayer and consequently creating void space among the surfactant molecules [13]. Both surfactant and cosurfactant in SEDDS are used to reduce the interfacial tension. So for simplification purpose, we combined the descriptors of surfactant and cosurfactant together. The overall descriptor was calculated as follows:

$$\text{Descriptor of Smix} = R_s \times D_s + R_{\text{cos}} \times D_{\text{cos}}, \quad (1)$$

where R_s is the ratio (w/w) of surfactant; D_s is the molecular descriptor of lipophilic segment of surfactant. R_{cos} is the

TABLE 3: Equations of statistical parameters.

Parameter	Equation
MSE	$MSE = (1/n) \sum_{i=1}^n (y_{\text{pred}} - y_{\text{exp}})^2$
RMSEP	$RMSEP = [(1/n) \sum_{i=1}^n (y_{\text{pred}} - y_{\text{exp}})^2]^{0.5}$
RSEP	$RSEP (\%) = 100 \times [\sum_{i=1}^n (y_{\text{pred}} - y_{\text{exp}})^2 / \sum_{i=1}^n (y_{\text{exp}})^2]^{0.5}$
MAE	$MAE (\%) = (100/n) \times \sum_{i=1}^n y_{\text{pred}} - y_{\text{exp}} $

y_{pred} and y_{exp} are predicted and experimental solubility values, respectively; n is the number of samples in the data set.

ratio (w/w) of cosurfactant; Dcos is the molecular descriptor of cosurfactant.

The descriptors were selected to make a stable and interpretable model. A three-stage manual descriptor selection process was performed: (1) descriptors with too many zero values or the same values (descriptors of Tween HS) were eliminated; (2) descriptors with very small standard deviation values (<0.5%) were removed; (3) a particular descriptor was chosen to represent a group of highly correlated variables (correlation coefficients >0.80), thereby minimizing the redundancy and overlapping of the descriptors. Since the ranges of descriptor values influence the quality of the models generated, we normalized the rest descriptor values to a range of 0 to 1 [28].

2.4. QSPR Modeling. To begin the model development process, the solubility data of drugs in formula 1–6 were split into a training set (80% of the total number of formulations) and an internal validation set (20% of the total number of formulations) randomly. The solubility data of drugs in formula 7–8 were used as a predicting set. The selected descriptors in Section 2.3 were regressed against the solubility of the training set by means of multiple linear regression (MLR). The best equations were determined based on the highest squared multiple correlation coefficient (R^2), Fisher ration (F), and lowest standard error (s).

Artificial neural network (ANN) is a proper method for modeling nonlinear relationship [29]. It was also attempted to develop the better predictive models. All networks used in this study were three-layered back-propagation (BP) type. The input data included the descriptors selected in linear models, and the output neuron referred to the solubility values of drugs in SEDDS. Sigmoid transfer functions were used in all layers. The number of neurons in the hidden layer was adjusted to optimize the network, and the best model gave the highest correlation coefficient (r) and the lowest MSE. The internal validation set (18 formulations) was used to prevent the overfitting.

2.5. Statistical Analysis. To evaluate the predictive ability of QSPR models, the statistical parameters of mean square error (MSE), root mean square error of prediction (RMSEP), the RMSE, the relative standard error of prediction (RSEP), and mean absolute error (MAE) [30] were used. Table 3 shows these equations.

3. Results and Discussion

3.1. QSPR Models. Table 4 shows the solubility of 2-APA-NSAIDs in various formulations.

3.1.1. MLR. The best MLR models were given as follows:

$$\begin{aligned}
 S_{\text{ketoprofen}} &= 1.073(\pm 0.068) + 1.176(\pm 0.073)SR \\
 &\quad + 0.316(\pm 0.031)OR - 0.165(\pm 0.046) \\
 &\quad \times O\text{-ABSQ} - 0.511(\pm 0.048)O\text{-E}_{\text{LUMO}} \\
 &\quad + 0.125(\pm 0.085)S\text{-Volume} \\
 &\quad + 0.176(\pm 0.072)S\text{-Dipole}, \\
 S_{\text{ibuprofen}} &= 1.346(\pm 0.112) + 1.578(\pm 0.120)SR \\
 &\quad + 0.935(\pm 0.051)OR - 0.170(\pm 0.076) \\
 &\quad \times O\text{-ABSQ} - 0.056(\pm 0.078)O\text{-E}_{\text{LUMO}} \\
 &\quad + 0.242(\pm 0.140)S\text{-Volume} \\
 &\quad + 0.329(\pm 0.118)S\text{-Dipole}, \\
 S_{\text{flurbiprofen}} &= 0.685(\pm 0.057) + 0.641(\pm 0.061)SR \\
 &\quad + 0.28(\pm 0.026)OR + 0.277(\pm 0.039) \\
 &\quad \times O\text{-ABSQ} - 0.063(\pm 0.040)O\text{-E}_{\text{LUMO}} \\
 &\quad + 0.364(\pm 0.071)S\text{-Volume} \\
 &\quad - 0.153(\pm 0.060)S\text{-Dipole}, \\
 S_{\text{naproxen}} &= 0.239(\pm 0.017) + 0.222(\pm 0.016)SR \quad (2) \\
 &\quad + 0.030(\pm 0.009)OR + 0.024(\pm 0.010) \\
 &\quad \times O\text{-Dipole} + 0.178(\pm 0.018)O\text{-ABSQ} \\
 &\quad - 0.039(\pm 0.016)O\text{-MaxQ}^- + 0.077 \\
 &\quad \times (\pm 0.032)S\text{-Volume} + 0.097 \\
 &\quad \times (\pm 0.032)S\text{-MaxQ}^-, \\
 S_{\text{loxooprofen}} &= 1.452(\pm 0.103) + 0.996(\pm 0.110)SR \\
 &\quad + 0.285(\pm 0.047)OR + 0.070(\pm 0.070) \\
 &\quad \times O\text{-ABSQ} - 0.222(\pm 0.071)O\text{-E}_{\text{LUMO}} \\
 &\quad + 0.059(\pm 0.128)S\text{-Volume} \\
 &\quad + 0.237(\pm 0.108)S\text{-Dipole}, \\
 S_{\text{carprofen}} &= 0.212(\pm 0.058) + 0.999(\pm 0.065)SR \\
 &\quad + 0.182(\pm 0.032)OR + 0.268(\pm 0.048) \\
 &\quad \times O\text{-ABSQ} + 1.157(\pm 0.069)S\text{-Volume} \\
 &\quad + 0.550(\pm 0.072)S\text{-Dipole}.
 \end{aligned}$$

In all the equations, variable inflation factor (VIF) was less than 10, suggesting the absence of multicollinearity. As

FIGURE 2: Experimental versus predicted solubility for MLR and ANN; (a) ketoprofen, (b) ibuprofen, (c) flurbiprofen, (d) naproxen, (e) loxoprofen, (f) carprofen.

TABLE 4: Solubility of drugs in SEDDS.

NO.	Formula	Km	Oil : Smix	S _{Keto} (mg·mL ⁻¹)	S _{Ibu} (mg·mL ⁻¹)	S _{Flu} (mg·mL ⁻¹)	S _{Nap} (mg·mL ⁻¹)	S _{Loxo} (mg·mL ⁻¹)	S _{car} (mg·mL ⁻¹)
1 ^a	1	1:2	0.5:9.5	0.961	1.756	0.848	0.332	1.909	0.989
2 ^a	1	1:2	1:9	1.207	2.075	0.948	0.350	2.002	1.014
3 ^a	1	1:2	1.5:8.5	1.439	2.634	1.014	0.366	2.422	1.086
4 ^a	1	1:1	0.5:9.5	1.519	2.293	1.054	0.423	2.072	1.139
5 ^b	1	1:1	1:9	1.464	2.552	1.199	0.426	2.144	1.146
6 ^a	1	1:1	1.5:8.5	1.864	2.958	1.315	0.420	2.431	1.321
7 ^a	1	2:1	0.5:9.5	1.825	2.436	1.442	0.553	2.131	1.502
8 ^a	1	2:1	1:9	1.943	2.995	1.541	0.554	2.209	1.594
9 ^b	1	2:1	1.5:8.5	1.674	3.221	1.564	0.552	2.457	1.689
10 ^a	1	3:1	0.5:9.5	2.033	2.678	1.535	0.592	2.177	1.633
11 ^a	1	3:1	1:9	2.354	3.06	1.598	0.594	2.387	1.605
12 ^a	1	3:1	1.5:8.5	2.485	3.355	1.705	0.569	2.499	1.757
13 ^b	1	4:1	0.5:9.5	2.155	2.762	1.541	0.596	2.355	1.842
14 ^a	1	4:1	1:9	2.438	3.112	1.647	0.618	2.497	1.871
15 ^a	1	4:1	1.5:8.5	2.220	3.520	1.714	0.582	2.510	1.799
16 ^a	2	1:2	0.5:9.5	0.798	1.538	0.933	0.397	1.522	0.957
17 ^a	2	1:2	1:9	0.845	1.899	0.958	0.403	1.563	0.964
18 ^a	2	1:2	1.5:8.5	0.856	2.164	1.042	0.390	1.475	0.956
19 ^b	2	1:1	0.5:9.5	1.057	2.074	1.045	0.450	1.904	1.475
20 ^a	2	1:1	1:9	1.295	2.444	1.228	0.466	1.928	1.498
21 ^a	2	1:1	1.5:8.5	1.196	2.577	1.535	0.514	1.877	1.491
22 ^a	2	2:1	0.5:9.5	1.438	2.608	1.465	0.609	2.165	1.777
23 ^a	2	2:1	1:9	1.353	2.824	1.569	0.620	2.091	1.836
24 ^a	2	2:1	1.5:8.5	1.430	3.099	1.666	0.631	2.186	1.88
25 ^a	2	3:1	0.5:9.5	1.577	2.706	1.716	0.647	2.215	1.923
26 ^a	2	3:1	1:9	1.665	3.066	1.740	0.646	2.082	2.103
27 ^b	2	3:1	1.5:8.5	1.600	3.418	1.830	0.696	2.229	2.009
28 ^a	2	4:1	0.5:9.5	1.637	2.770	1.749	0.703	2.310	2.165
29 ^a	2	4:1	1:9	1.705	3.176	1.791	0.694	2.268	2.171
30 ^a	2	4:1	1.5:8.5	1.640	3.816	1.959	0.715	2.358	2.113
31 ^a	3	1:2	0.5:9.5	0.840	1.495	0.839	0.414	1.483	1.378
32 ^b	3	1:2	1:9	1.018	2.356	1.015	0.437	1.653	1.405
33 ^a	3	1:2	1.5:8.5	1.027	2.432	1.030	0.399	1.771	1.407
34 ^a	3	1:1	0.5:9.5	1.217	2.243	1.202	0.587	1.930	1.903
35 ^a	3	1:1	1:9	1.183	2.407	1.244	0.530	1.937	1.894
36 ^b	3	1:1	1.5:8.5	1.330	2.918	1.300	0.497	2.100	1.939
37 ^a	3	2:1	0.5:9.5	1.537	2.573	1.393	0.637	2.331	2.307
38 ^a	3	2:1	1:9	1.739	3.148	1.638	0.627	2.396	2.404
39 ^b	3	2:1	1.5:8.5	1.631	3.352	1.670	0.624	2.339	2.366
40 ^a	3	3:1	0.5:9.5	1.746	3.059	1.644	0.651	2.552	2.637
41 ^a	3	3:1	1:9	1.803	3.494	1.752	0.680	2.458	2.659
42 ^a	3	3:1	1.5:8.5	1.755	3.674	1.826	0.705	2.344	2.46
43 ^a	3	4:1	0.5:9.5	1.935	3.216	1.815	0.765	2.606	2.714
44 ^a	3	4:1	1:9	1.874	3.554	1.831	0.739	2.608	2.757
45 ^a	3	4:1	1.5:8.5	2.033	3.687	2.012	0.749	2.439	2.676
46 ^b	4	1:2	0.5:9.5	0.944	1.545	0.794	0.342	1.585	0.818
47 ^a	4	1:2	1:9	0.961	1.969	0.950	0.359	1.426	0.729
48 ^a	4	1:2	1.5:8.5	0.980	2.448	0.985	0.345	1.489	0.853
49 ^a	4	1:1	0.5: 9.5	1.302	2.219	1.047	0.438	1.844	1.102
50 ^a	4	1:1	1:9	1.316	2.754	1.134	0.476	1.722	1.262
51 ^a	4	1:1	1.5:8.5	1.451	3.137	1.310	0.441	2.136	1.103
52 ^b	4	2:1	0.5:9.5	1.671	2.23	1.071	0.444	2.081	1.553

TABLE 4: Continued.

NO.	Formula	Km	Oil: Smix	S_{Keto} (mg·mL ⁻¹)	S_{Ibu} (mg·mL ⁻¹)	S_{Flu} (mg·mL ⁻¹)	S_{Nap} (mg·mL ⁻¹)	S_{Loxo} (mg·mL ⁻¹)	S_{car} (mg·mL ⁻¹)
53 ^a	4	2:1	1:9	1.711	2.782	1.351	0.484	2.053	1.642
54 ^a	4	2:1	1.5:8.5	1.863	3.328	1.316	0.442	2.422	1.496
55 ^b	4	3:1	0.5:9.5	1.962	2.483	1.095	0.455	2.133	1.725
56 ^a	4	3:1	1:9	2.006	3.172	1.356	0.489	2.447	1.663
57 ^a	4	3:1	1.5:8.5	2.130	3.946	1.344	0.461	2.470	1.801
58 ^a	4	4:1	0.5:9.5	2.092	2.545	1.168	0.458	2.427	1.94
59 ^b	4	4:1	1:9	2.124	3.380	1.385	0.503	2.519	1.892
60 ^a	4	4:1	1.5:8.5	1.999	4.062	1.431	0.491	2.639	1.945
61 ^a	5	1:2	0.5:9.5	0.816	1.609	0.921	0.442	1.606	0.807
62 ^b	5	1:2	1:9	0.854	2.017	0.980	0.440	1.649	1.208
63 ^a	5	1:2	1.5:8.5	0.876	2.101	1.002	0.423	1.701	1.273
64 ^a	5	1:1	0.5:9.5	0.985	1.945	1.344	0.525	1.945	1.577
65 ^a	5	1:1	1:9	1.227	2.211	1.343	0.561	2.001	1.646
66 ^a	5	1:1	1.5:8.5	1.246	2.713	1.424	0.548	2.064	1.699
67 ^a	5	2:1	0.5:9.5	1.398	2.662	1.544	0.689	2.134	2.134
68 ^b	5	2:1	1:9	1.610	2.853	1.678	0.678	2.286	2.010
69 ^a	5	2:1	1.5:8.5	1.617	3.307	1.819	0.655	2.419	2.199
70 ^a	5	3:1	0.5:9.5	1.558	2.932	1.774	0.735	2.268	2.256
71 ^a	5	3:1	1:9	1.747	3.260	1.698	0.693	2.355	2.416
72 ^b	5	3:1	1.5:8.5	1.791	3.617	1.841	0.694	2.495	2.300
73 ^a	5	4:1	0.5:9.5	1.617	2.985	1.820	0.766	2.337	2.454
74 ^a	5	4:1	1:9	1.921	3.393	1.953	0.760	2.374	2.505
75 ^a	5	4:1	1.5:8.5	1.812	3.685	2.055	0.752	2.503	2.429
76 ^a	6	1:2	0.5:9.5	0.839	1.769	0.849	0.381	1.544	1.439
77 ^b	6	1:2	1:9	0.906	2.163	0.951	0.371	1.665	1.32
78 ^a	6	1:2	1.5:8.5	1.066	2.414	1.135	0.402	1.712	1.392
79 ^a	6	1:1	0.5:9.5	1.237	2.203	1.242	0.485	1.794	1.759
80 ^a	6	1:1	1:9	1.537	2.349	1.299	0.510	1.869	1.811
81 ^a	6	1:1	1.5:8.5	1.513	2.938	1.527	0.540	1.962	1.88
82 ^a	6	2:1	0.5:9.5	1.581	2.455	1.437	0.636	1.912	2.331
83 ^b	6	2:1	1:9	1.711	2.686	1.559	0.631	2.069	2.258
84 ^a	6	2:1	1.5:8.5	1.721	3.068	1.728	0.656	2.143	2.406
85 ^b	6	3:1	0.5:9.5	1.768	2.710	1.647	0.668	2.295	2.500
86 ^a	6	3:1	1:9	1.980	3.265	1.775	0.659	2.652	2.657
87 ^a	6	3:1	1.5:8.5	1.949	3.709	1.924	0.686	2.595	2.421
88 ^a	6	4:1	0.5:9.5	1.959	3.256	1.781	0.685	2.572	2.728
89 ^a	6	4:1	1:9	1.984	3.646	1.860	0.694	2.729	2.806
90 ^a	6	4:1	1.5:8.5	2.155	3.742	2.069	0.725	2.798	2.793

^aTraining set.^bInternal validation set.

shown in Table 5, the correlation matrix for these descriptors shows no high correlation between variables and could be used to develop QSPR models. The statistical results indicate that these equations represent good models for calculating the solubility (Table 6).

Models in (2) shows the significance of the combination of SR, OR, O-MaxQ⁻, O-ABSQ, O-E_{LUMO}, S-Volume, and S-Dipole in the solubility of drugs in SEDDS. According to *t*-test criterion, the most important descriptor is SR. The positive coefficient suggests that high-concentration surfactant will increase the solubility. Surfactant plays an impor-

tant role in O/W microemulsion/emulsion formation: it forms a layer around emulsion droplets, which reduces the interfacial energy and provides a mechanical barrier to coalescence [31]. And the result suggests that drugs are mainly dissolved in the phase of surfactant.

The specific effect of O-MaxQ⁻, O-ABSQ, and S-Dipole to the solubility depends on the drug type.

2.4. QSPR Modeling. ANN models were constructed with the same descriptors as in MLR models using Leavenberg-Marquardt (LM) algorithm as activity function. The proper

TABLE 5: Correlation matrix for selected descriptors.

	SR	OR	O-dipole	O-MaxQ ⁻	O-ABSQ	O-LUMO	S-volume	S-dipole	S-MaxQ ⁻
SR	1.000	-0.170	0.003	-0.003	0.065	0.045	0.671	-0.615	0.617
OR		1.000	0.011	0.053	-0.143	-0.025	-0.049	-0.041	0.027
O-dipole			1.000	-0.295	-0.153	0.652	-0.141	-0.214	-0.111
O-MaxQ ⁻				1.000	-0.158	-0.295	-0.020	0.521	0.439
O-ABSQ					1.000	0.159	0.345	0.111	-0.163
O-LUMO						1.000	0.472	-0.130	0.195
S-volume							1.000	-0.333	0.704
S-dipole								1.000	-0.057
S-MaxQ ⁻									1.000

TABLE 6: Statistical qualities of different models.

Model	<i>n</i>	<i>R</i> ²	MSE	RMSEP	RSEP (%)	MAE (%)	Model	<i>n</i>	<i>R</i> ²	MSE	RMSEP	RSEP (%)	MAE (%)
1 ^{MLR}	72	0.948	0.0094	0.097	5.999	7.9375	7 ^{ANN}	72	0.989	0.0080	0.089	5.507	5.993
2 ^{MLR}	72	0.932	0.0254	0.159	5.539	13.402	8 ^{ANN}	72	0.994	0.0089	0.094	3.269	5.112
3 ^{MLR}	72	0.943	0.0065	0.081	5.417	6.204	9 ^{ANN}	72	0.994	0.0037	0.061	4.098	4.190
4 ^{MLR}	72	0.949	0.0008	0.028	4.942	2.292	10 ^{ANN}	72	0.993	0.0003	0.016	2.778	1.209
5 ^{MLR}	72	0.822	0.0213	0.1459	6.683	12.053	11 ^{ANN}	72	0.989	0.0046	0.0677	3.100	5.243
6 ^{MLR}	72	0.967	0.0104	0.1019	5.326	8.316	12 ^{ANN}	72	0.990	0.0089	0.0943	4.928	6.272

TABLE 7: Experimental and predicted values of predicting set.

(a)

NO.	S _{Keto} Exp.	MLR	ANN	S _{Ibu} Exp.	MLR	ANN	S _{Flu} Exp.	MLR	ANN
1 ^a	1.464	1.649	1.376	2.552	2.457	2.488	1.199	1.195	1.241
2 ^a	1.674	2.090	2.104	3.221	3.299	3.285	1.564	1.572	1.518
3 ^a	2.155	2.230	2.378	2.762	2.973	2.663	1.541	1.608	1.615
4 ^a	1.057	1.026	1.169	2.074	1.983	2.233	1.045	1.209	1.233
5 ^a	1.600	1.756	1.631	3.418	3.487	3.420	1.830	1.801	1.885
6 ^a	1.018	0.901	0.841	2.356	2.099	2.014	1.015	0.964	0.871
7 ^a	1.330	1.363	1.106	2.918	2.970	2.973	1.300	1.395	1.191
8 ^a	1.631	1.693	1.422	3.352	3.407	3.655	1.670	1.699	1.615
9 ^a	0.944	0.913	0.461	1.545	1.663	2.033	0.794	0.645	0.967
10 ^a	1.671	1.644	1.504	2.230	2.631	2.274	1.071	1.189	1.046
11 ^a	1.962	1.832	1.767	2.483	2.881	2.543	1.095	1.328	1.090
12 ^a	2.124	2.011	2.093	3.380	3.373	3.396	1.385	1.501	1.425
13 ^a	0.854	0.794	1.050	2.017	1.909	1.828	0.980	1.049	0.958
14 ^a	1.610	1.519	1.542	2.853	2.880	2.794	1.678	1.640	1.593
15 ^a	1.791	1.773	1.775	3.617	3.476	3.584	1.841	1.881	1.971
16 ^a	0.906	0.994	1.183	2.163	2.075	1.830	0.951	1.084	1.043
17 ^a	1.711	1.718	1.775	2.686	3.044	2.975	1.559	1.646	1.624
18 ^a	1.768	1.827	1.788	2.710	2.934	2.976	1.647	1.694	1.691
19 ^b	1.452	1.047	1.223	1.801	1.978	1.947	1.065	1.173	1.062
20 ^b	1.657	1.132	1.443	2.314	2.346	2.265	1.217	1.273	1.193
21 ^b	1.614	1.241	1.476	2.261	2.748	2.749	1.369	1.386	1.315
22 ^b	1.778	1.402	1.530	2.255	2.447	2.732	1.322	1.444	1.375
23 ^b	1.901	1.486	1.708	2.516	2.816	2.842	1.645	1.544	1.345
24 ^b	2.000	1.571	1.837	2.757	3.185	3.413	1.630	1.644	1.552
25 ^b	1.887	1.591	1.680	2.304	2.699	2.751	1.342	1.587	1.596
26 ^b	2.009	1.675	1.911	2.938	3.068	3.152	1.765	1.687	1.490

(a) Continued.

NO.	S _{Keto} Exp.	MLR	ANN	S _{Ibu} Exp.	MLR	ANN	S _{Flu} Exp.	MLR	ANN
27 ^b	2.165	1.735	1.988	3.140	3.404	3.810	1.786	1.773	1.625
28 ^b	2.056	1.710	1.774	2.377	2.856	2.754	1.477	1.675	1.661
29 ^b	2.062	1.770	1.991	2.944	3.192	3.273	1.687	1.761	1.582
30 ^b	2.206	1.830	2.071	3.603	3.528	3.916	1.632	1.848	1.654
31 ^b	1.534	1.092	1.080	1.933	2.053	2.149	1.171	1.162	1.062
32 ^b	1.653	1.177	1.144	2.142	2.422	2.205	1.339	1.262	1.194
33 ^b	1.622	1.286	1.068	2.195	2.824	2.822	1.435	1.376	1.233
34 ^b	1.812	1.457	1.344	2.327	2.542	2.753	1.574	1.464	1.381
35 ^b	1.802	1.541	1.521	2.347	2.911	3.096	1.770	1.564	1.415
36 ^b	1.721	1.626	1.471	2.833	3.280	3.551	1.787	1.664	1.483
37 ^b	1.852	1.651	1.494	2.247	2.803	3.085	1.685	1.621	1.657
38 ^b	1.796	1.736	1.698	2.165	3.172	3.504	1.690	1.721	1.586
39 ^b	1.820	1.796	1.733	2.865	3.508	3.771	1.877	1.808	1.662
40 ^b	1.916	1.773	1.604	2.129	2.967	3.157	1.767	1.718	1.796
41 ^b	2.133	1.833	1.779	2.529	3.303	3.627	1.855	1.805	1.691
42 ^b	1.884	1.893	1.885	3.116	3.639	3.948	1.884	1.891	1.778

(b)

NO.	S _{Nap} Exp.	MLR	ANN	S _{Loxo} Exp.	MLR	ANN	S _{Car} Exp.	MLR	ANN
1 ^a	0.426	0.438	0.441	2.144	2.104	2.175	1.146	1.227	1.193
2 ^a	0.552	0.534	0.531	2.457	2.465	2.462	1.689	1.641	1.680
3 ^a	0.596	0.612	0.606	2.355	2.549	2.201	1.842	1.913	1.698
4 ^a	0.450	0.505	0.479	1.904	1.728	1.884	1.475	1.357	1.378
5 ^a	0.696	0.651	0.672	2.229	2.347	2.260	2.009	2.132	2.082
6 ^a	0.437	0.435	0.403	1.653	1.742	1.505	1.405	1.449	1.505
7 ^a	0.497	0.553	0.518	2.100	2.112	2.127	1.939	1.939	1.884
8 ^a	0.624	0.661	0.631	2.339	2.360	2.300	2.366	2.359	2.326
9 ^a	0.342	0.312	0.315	1.585	1.520	1.620	0.818	0.769	1.006
10 ^a	0.444	0.473	0.491	2.081	2.100	2.099	1.553	1.495	1.606
11 ^a	0.455	0.514	0.485	2.133	2.250	2.313	1.725	1.681	1.808
12 ^a	0.503	0.536	0.488	2.419	2.404	2.455	1.892	1.805	1.879
13 ^a	0.440	0.456	0.435	1.649	1.666	1.574	1.208	1.175	1.346
14 ^a	0.678	0.650	0.661	2.286	2.233	2.339	2.010	2.065	2.313
15 ^a	0.694	0.697	0.708	2.435	2.445	2.379	2.300	2.305	2.361
16 ^a	0.371	0.402	0.389	1.665	1.706	1.514	1.320	1.501	1.505
17 ^a	0.631	0.618	0.621	2.069	2.279	2.258	2.258	2.338	2.381
18 ^a	0.668	0.673	0.651	2.295	2.352	2.336	2.500	2.529	2.624
19 ^b	0.403	0.536	0.528	1.774	1.858	1.825	1.318	1.362	1.239
20 ^b	0.480	0.537	0.528	1.660	1.938	1.904	1.409	1.390	1.489
21 ^b	0.501	0.543	0.512	1.601	2.039	2.220	1.358	1.440	1.709
22 ^b	0.544	0.628	0.650	2.054	2.138	2.046	1.632	1.730	1.677
23 ^b	0.514	0.629	0.633	2.333	2.218	2.346	1.776	1.759	1.957
24 ^b	0.537	0.631	0.611	2.223	2.298	2.463	1.753	1.787	2.133
25 ^b	0.593	0.677	0.692	2.250	2.288	2.163	1.788	1.925	1.804
26 ^b	0.734	0.678	0.673	2.405	2.368	2.516	2.008	1.954	2.063
27 ^b	0.602	0.674	0.659	2.309	2.428	2.544	2.050	1.961	2.160
28 ^b	0.630	0.707	0.716	2.418	2.382	2.242	2.060	2.046	1.890
29 ^b	0.724	0.703	0.693	2.493	2.442	2.585	2.163	2.054	2.116
30 ^b	0.682	0.700	0.686	2.417	2.501	2.588	2.230	2.061	2.167
31 ^b	0.686	0.499	0.546	1.944	1.846	1.681	1.627	1.478	1.430
32 ^b	0.852	0.500	0.525	1.933	1.926	1.862	1.731	1.507	1.544
33 ^b	0.742	0.506	0.482	2.037	2.027	2.195	1.725	1.556	1.746

(b) Continued.

NO.	S _{Nap} Exp.	MLR	ANN	S _{Loxo} Exp.	MLR	ANN	S _{Car} Exp.	MLR	ANN
34 ^b	0.489	0.599	0.675	2.274	2.131	2.076	1.966	1.940	1.945
35 ^b	0.529	0.600	0.641	2.313	2.211	2.357	2.077	1.969	2.028
36 ^b	0.499	0.601	0.619	2.363	2.291	2.426	2.012	1.998	2.097
37 ^b	0.595	0.651	0.729	2.449	2.283	2.263	2.271	2.182	2.172
38 ^b	0.586	0.652	0.705	2.493	2.363	2.490	2.003	2.211	2.219
39 ^b	0.579	0.648	0.689	2.437	2.423	2.527	2.268	2.218	2.244
40 ^b	0.761	0.683	0.778	2.265	2.379	2.363	2.474	2.331	2.325
41 ^b	0.732	0.680	0.751	2.446	2.438	2.539	2.356	2.339	2.375
42 ^b	0.791	0.676	0.732	2.500	2.498	2.603	2.544	2.347	2.383

^a Internal validation set.^b External prediction set.

TABLE 8: Statistical comparison between MLR and ANN.

Model	N	MSE	RMSEP	RSEP (%)	MAE (%)	Model	n	MSE	RMSEP	RSEP (%)	MAE (%)
1 ^{MLR}	42	0.072	0.268	15.405	21.436	7 ^{ANN}	42	0.065	0.255	14.677	21.168
2 ^{MLR}	42	0.147	0.384	14.605	29.965	8 ^{ANN}	42	0.258	0.508	19.351	38.576
3 ^{MLR}	42	0.011	0.106	7.074	8.506	9 ^{ANN}	42	0.021	0.146	9.701	11.573
4 ^{MLR}	42	0.010	0.100	15.649	6.965	10 ^{ANN}	42	0.007	0.086	13.565	5.735
5 ^{MLR}	42	0.014	0.119	5.445	8.487	11 ^{ANN}	42	0.024	0.156	7.119	11.207
6 ^{MLR}	42	0.010	0.100	5.270	8.039	12 ^{ANN}	42	0.020	0.141	7.411	11.066

number of neurons in the hidden layer was set as 10 to ensure the lowest mean square error (MSE). Table 6 shows the statistical qualities of the ANN models, compared with MLR models. R^2 of QSPR models indicate that they can explain more than 90% of the variation in the formulations, which correspond to a significant explanatory capacity.

3.2. QSPR Models for Solubility Prediction. Table 7 shows the solubility prediction for the internal and external validation sets obtained from these models. As shown in Figures 2(a)–2(f), the plots of experimental values versus predicted values obtained by the MLR and ANN modeling indicate good correlations between the experimental and predicted values and confirm the satisfied predictive ability of QSPR models.

A statistical evaluation of both MLR and ANN models is shown in Table 8. According to the comparison between the two models in this study, except for the model drugs of ketoprofen and naproxen, MLR was found to be more reliable for the solubility prediction than ANN.

Based on the models, the optimal formulations in internal validation set were as follows: oleic acid/Tween20/ethanol (Km = 4:1, 0.5:9.5) for ketoprofen; butyl oleate/Tween40/isopropyl alcohol (Km = 3:1, 1.5:8.5) for ibuprofen, flurbiprofen, and naproxen; oleic acid/Tween20/Ethanol (Km = 2:1, 1.5:8.5) for loxoprofen; methyl oleate/Tween80/diethylene glycol monoethyl ether for carprofen. The best formulations for the predicting set were as follows: butyl oleate/Tween20/isopropyl alcohol (Km = 4:1, 1.5:8.5) for ketoprofen and ibuprofen; ethyl oleate/Tween40/ethanol (Km = 4:1, 1.5:8.5) for flurbiprofen, loxoprofen, and carprofen; butyl oleate/Tween20/isopropyl alcohol (Km = 4:1, 0.5:9.5) for naproxen. All

the predicted optimum formulations were consistent with the experimental ones except for naproxen, indicating the significance of the models in formulation screening.

3.3. The Drug Effect on the Solubility. To examine the influence of drugs on the solubility, the descriptors of drugs (X) were correlated with the drug solubility in different formulations (Y). The multiple linear regression analyses gave the following equations:

$$\begin{aligned}
 S_{\text{Formula 1}} = & 3.710(\pm 0.138) + 0.793(\pm 0.058)\text{SR} \\
 & + 0.368(\pm 0.047)\text{OR} + 2.453(\pm 0.162)\text{D-Dipole} \\
 & - 2.457(\pm 0.074)\text{D-MaxQ}^+ \\
 & - 1.245(\pm 0.071)\text{D-E}_{\text{HOMO}} \\
 & - 2.670(\pm 0.121)\text{D-Wiener} \\
 & + 0.978(\pm 0.162)\text{D-LogD},
 \end{aligned}$$

$$n = 90, R^2 = 0.953, s = 0.178,$$

$$F = 237.739, \text{MSE} = 0.029,$$

$$\begin{aligned}
 S_{\text{Formula 2}} = & 2.241(\pm 0.137) + 1.002(\pm 0.058)\text{SR} \\
 & + 0.293(\pm 0.046)\text{OR} \\
 & + 2.994(\pm 0.160)\text{D-Dipole} \\
 & - 1.801(\pm 0.074)\text{D-MaxQ}^+
 \end{aligned}$$

$$\begin{aligned}
 & -0.454(\pm 0.070)D-E_{\text{HOMO}} \\
 & -3.122(\pm 0.120)D\text{-Wiener} \\
 & +1.770(\pm 0.160)D\text{-LogD},
 \end{aligned}$$

$$n = 90, R^2 = 0.948, s = 0.177,$$

$$F = 214.550, \text{MSE} = 0.028,$$

$$\begin{aligned}
 S_{\text{Formula 3}} = & 1.693(\pm 0.147) + 1.119(\pm 0.062)SR \\
 & + 0.301(\pm 0.050)OR + 4.343(\pm 0.172)D\text{-Dipole} \\
 & - 1.972(\pm 0.079)D\text{-MaxQ}^+ \\
 & - 0.379(\pm 0.075)D-E_{\text{HOMO}} \\
 & - 3.864(\pm 0.129)D\text{-Wiener} \\
 & + 2.931(\pm 0.172)D\text{-LogD},
 \end{aligned}$$

$$n = 90, R^2 = 0.952, s = 0.190,$$

$$F = 234.809, \text{MSE} = 0.033,$$

$$\begin{aligned}
 S_{\text{Formula 4}} = & 3.215(\pm 0.200) + 0.942(\pm 0.085)SR \\
 & + 0.409(\pm 0.068)OR \\
 & + 2.985(\pm 0.234)D\text{-Dipole} \\
 & - 2.428(\pm 0.108)D\text{-MaxQ}^+ \\
 & - 1.226(\pm 0.102)D-E_{\text{HOMO}} \\
 & - 3.167(\pm 0.176)D\text{-Wiener} \\
 & + 1.616(\pm 0.234)D\text{-LogD},
 \end{aligned}$$

$$n = 90, R^2 = 0.914, s = 0.258,$$

$$F = 123.981, \text{MSE} = 0.061,$$

$$\begin{aligned}
 S_{\text{Formula 5}} = & 1.925(\pm 0.147) + 1.113(\pm 0.062)SR \\
 & + 0.355(\pm 0.050)OR \\
 & + 3.447(\pm 0.172)D\text{-Dipole} \\
 & - 1.827(\pm 0.079)D\text{-MaxQ}^+ \\
 & - 0.334(\pm 0.075)D-E_{\text{HOMO}} \\
 & - 3.335(\pm 0.129)D\text{-Wiener} \\
 & + 2.166(\pm 0.172)D\text{-LogD},
 \end{aligned}$$

$$n = 90, R^2 = 0.946, s = 0.190,$$

$$F = 204.247, \text{MSE} = 0.033,$$

$$\begin{aligned}
 S_{\text{Formula 6}} = & 1.708(\pm 0.151) + 1.135(\pm 0.064)SR \\
 & + 0.385(\pm 0.051)OR + 4.076(\pm 0.177)D\text{-Dipole} \\
 & - 1.907(\pm 0.081)D\text{-MaxQ}^+ \\
 & - 0.415(\pm 0.077)D-E_{\text{HOMO}}
 \end{aligned}$$

$$-3.579(\pm 0.133)D\text{-Wiener}$$

$$+2.598(\pm 0.177)D\text{-LogD},$$

$$n = 90, R^2 = 0.948, s = 0.195,$$

$$F = 212.012, \text{MSE} = 0.035.$$

(3)

Equation (3) reveals a significant effect of the shape-related descriptor (Wiener index), charge-related descriptor (MaxQ^+ , Dipole moment), quantum chemical parameter (E_{HOMO}), and logD on the solubility of 2-APA-NSAIDs in SEDDS. According to *t*-test criterion, the most important factors are Dipole, MaxQ^+ , wiener index, and logD. The negative coefficient of wiener index showed that a drug with small size tended to have a good solubility in SEDDS. The positive coefficient of logD indicated that the increase of lipophilicity favors the solubility.

4. Conclusions

In the present study, we used QSPR to predict the solubility of 2-APA-NSAIDs in self-emulsifying drug delivery system by means of linear and nonlinear methods. We examined the effects of component ratio, stereoscopic effect, hydrophobic interactions, and electric effect on the solubility by MLR and ANN. In all the models, the ratio of compositions (SR, OR), charge-related descriptor, and the quantum chemical parameter (E_{HOMO}) appeared to be the most important factors. The obtained models in (3) indicate the significance of wiener index, charge-related descriptor, and logD of drugs on the solubility. The results of MLR and ANN methods were satisfactory, and nonlinear models were not found to be superior to linear models. Since the predicted optimum formulations were consistent with the experimental ones, the QSPR models obtained would be useful to predict the solubility of 2-APA-NSAIDs in SEDDS, screen for the optimal formulation, and reduce experimental time.

Acknowledgment

This study was supported by the National Natural Science Foundation of the People's Republic of China (Grant no. 30973659).

References

- [1] E. Atef and A. A. Belmonte, "Formulation and in vitro and in vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS)," *European Journal of Pharmaceutical Sciences*, vol. 35, no. 4, pp. 257–263, 2008.
- [2] K. Hussein, M. Türk, and M. A. Wahl, "Drug loading into β -cyclodextrin granules using a supercritical fluid process for improved drug dissolution," *European Journal of Pharmaceutical Sciences*, vol. 33, no. 3, pp. 306–312, 2008.
- [3] M. F. Francis, M. Piredda, and F. M. Winnik, "Solubilization of poorly water soluble drugs in micelles of hydrophobically modified hydroxypropylcellulose copolymers," *Journal of Controlled Release*, vol. 93, no. 1, pp. 59–68, 2003.

- [4] M. Rutnakornpituk, S. Meerod, B. Boontha, and U. Wichai, "Magnetic core-bilayer shell nanoparticle: a novel vehicle for entrapment of poorly water-soluble drugs," *Polymer*, vol. 50, no. 15, pp. 3508–3515, 2009.
- [5] T. Vasconcelos, B. Sarmento, and P. Costa, "Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs," *Drug Discovery Today*, vol. 12, no. 23–24, pp. 1068–1075, 2007.
- [6] C. W. Pouton, "Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-micro-emulsifying' drug delivery systems," *European Journal of Pharmaceutical Sciences*, vol. 11, no. S2, pp. S93–S98, 2000.
- [7] P. P. Constantinides, "Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects," *Pharmaceutical Research*, vol. 12, no. 11, pp. 1561–1572, 1995.
- [8] S. A. Charman, W. N. Charman, M. C. Rogge, T. D. Wilson, F. J. Dutko, and C. W. Pouton, "Self-emulsifying drug delivery systems: formulation and biopharmaceutical evaluation of an investigational lipophilic compound," *Pharmaceutical Research*, vol. 9, no. 1, pp. 87–93, 1992.
- [9] D. J. Hauss, S. E. Fogal, J. V. Ficorilli et al., "Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB₄ inhibitor," *Journal of Pharmaceutical Sciences*, vol. 87, no. 2, pp. 164–169, 1998.
- [10] C. J. Porter, A. M. Kaukonen, B. J. Boyd, G. A. Edwards, and W. N. Charman, "Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation," *Pharmaceutical Research*, vol. 21, no. 8, pp. 1405–1412, 2004.
- [11] T. R. Kommuru, B. Gurley, M. A. Khan, and I. K. Reddy, "Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment," *International Journal of Pharmaceutics*, vol. 212, no. 2, pp. 233–246, 2001.
- [12] G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison, "A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability," *Pharmaceutical Research*, vol. 12, no. 3, pp. 413–420, 1995.
- [13] R. N. Gursoy and S. Benita, "Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs," *Biomedicine and Pharmacotherapy*, vol. 58, no. 3, pp. 173–182, 2004.
- [14] I. I. Grover, I. I. Singh, and I. I. Bakshi, "Quantitative structure-property relationships in pharmaceutical research—part 1," *Pharmaceutical Science and Technology Today*, vol. 3, no. 1, pp. 28–35, 2000.
- [15] I. I. Grover, I. I. Singh, and I. I. Bakshi, "Quantitative structure-property relationships in pharmaceutical research—part 2," *Pharmaceutical Science and Technology Today*, vol. 3, no. 2, pp. 50–57, 2000.
- [16] Y. B. Liou, H. O. Ho, C. J. Yang, Y. K. Lin, and M. T. Sheu, "Construction of a quantitative structure-permeability relationship (QSPR) for the transdermal delivery of NSAIDs," *Journal of Controlled Release*, vol. 138, no. 3, pp. 260–267, 2009.
- [17] H. Y. Xu, J. W. Zou, Q. S. Yu, Y. H. Wang, J. Y. Zhang, and H. X. Jin, "QSPR/QSAR models for prediction of the physico-chemical properties and biological activity of polybrominated diphenyl ethers," *Chemosphere*, vol. 66, no. 10, pp. 1998–2010, 2007.
- [18] A. Talevi, M. Goodarzi, E. V. Ortiz et al., "Prediction of drug intestinal absorption by new linear and non-linear QSPR," *European Journal of Medicinal Chemistry*, vol. 46, no. 1, pp. 218–228, 2011.
- [19] A. Guerra, N. E. Campillo, and J. A. Pérez, "Neural computational prediction of oral drug absorption based on CODES 2D descriptors," *European Journal of Medicinal Chemistry*, vol. 45, no. 3, pp. 930–940, 2010.
- [20] T. Ghafourian, M. Barzegar-Jalali, S. Dastmalchi, T. Khavari-Khorasani, N. Hakimiha, and A. Nokhodchi, "QSPR models for the prediction of apparent volume of distribution," *International Journal of Pharmaceutics*, vol. 319, no. 1–2, pp. 82–97, 2006.
- [21] J. V. Turner, D. J. Maddalena, and D. J. Cutler, "Pharmacokinetic parameter prediction from drug structure using artificial neural networks," *International Journal of Pharmaceutics*, vol. 270, no. 1–2, pp. 209–219, 2004.
- [22] D. E. Mager, "Quantitative structure-pharmacokinetic/pharmacodynamic relationships," *Advanced Drug Delivery Reviews*, vol. 58, no. 12–13, pp. 1326–1356, 2006.
- [23] M. T. Saçan, M. Özkul, and S. S. Erdem, "QSPR analysis of the toxicity of aromatic compounds to the algae (*Scenedesmus obliquus*)," *Chemosphere*, vol. 68, no. 4, pp. 695–702, 2007.
- [24] M. O. Taha, H. Abdel-Halim, M. Al-Ghazawi, and E. Khalil, "QSPR modeling of pseudoternary microemulsions formulated employing lecithin surfactants: application of data mining, molecular and statistical modeling," *International Journal of Pharmaceutics*, vol. 295, no. 1–2, pp. 135–155, 2005.
- [25] T. Ghafourian, A. Safari, K. Adibkia, F. Parviz, and A. Nokhodchi, "A drug release study from hydroxypropylmethylcellulose (HPMC) matrices using QSPR modeling," *Journal of Pharmaceutical Sciences*, vol. 96, no. 12, pp. 3334–3351, 2007.
- [26] M. O. Taha, M. Al-Ghazawi, H. Abu-Amara, and E. Khalil, "Development of quantitative structure-property relationship models for pseudoternary microemulsions formulated with nonionic surfactants and cosurfactants: application of data mining and molecular modeling," *European Journal of Pharmaceutical Sciences*, vol. 15, no. 5, pp. 461–478, 2002.
- [27] M. Ruiz-Peña, R. Oropesa-Núñez, T. Pons, S. R. Louro, and A. Pérez-Gramatges, "Physico-chemical studies of molecular interactions between non-ionic surfactants and bovine serum albumin," *Colloids and Surfaces B Biointerfaces*, vol. 75, no. 1, pp. 282–289, 2010.
- [28] H. Zhang, Q. Y. Chen, M. L. Xiang, C. Y. Ma, Q. Huang, and S. Y. Yang, "In silico prediction of mitochondrial toxicity by using GA-CG-SVM approach," *Toxicology in Vitro*, vol. 23, no. 1, pp. 134–140, 2009.
- [29] S. Agatonovic-Kustrin and R. Beresford, "Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 22, no. 5, pp. 717–727, 2000.
- [30] M. Goodarzi, M. P. Freitas, and R. Jensen, "Ant colony optimization as a feature selection method in the QSAR modeling of anti-HIV-1 activities of 3-(3,5-dimethylbenzyl)uracil derivatives using MLR, PLS and SVM regressions," *Chemometrics and Intelligent Laboratory Systems*, vol. 98, no. 2, pp. 123–129, 2009.
- [31] B. K. Kang, J. S. Lee, S. K. Chon et al., "Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs," *International Journal of Pharmaceutics*, vol. 274, no. 1–2, pp. 65–73, 2004.